Cerebral Visual Impairment, Prematurity Complications, Retinopathy of Prematurity (ROP), Visual Field Defect
Conditions
Keywords
Retinopathy of Prematurity, Treatment, Laser, anti-vascular endothelial growth factor, Visual field defect, Cerebral visual impairment, Refractive errors, Prematurity
Brief summary
Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). This disease could lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) has become more common. In this study, the researchers will explore whether treatment of ROP affects visual function and retinal development. To explore this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina).
Detailed description
Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). The risk of ROP increases with lower gestational age and birth weight of the child. In a child born pre-term the blood vessels in the retina may not be fully developed. New - but unstructured - vessels could grow up from the retina and lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) into the eye has become more common. In this study, the researchers aim to explore whether treatment of ROP affects visual function and retinal development. To investigate this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina). The participants will undergo a comprehensive eye examination, including imaging of the retina, visual field testing, and biometric measurements. Their parents will also answer questions regarding cerebral visual impairment. Results from the group not treated for ROP will be compared to the treated subjects. Data will also be correlated with non-ocular parameters, such at gestational age, birth weight and brain hemorrhages.
Interventions
None listed
Sponsors
Oslo University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
6 Years to 20 Years
Healthy volunteers
No
Inclusion criteria
* Patients treated for ROP with either laser or injection of A-VEGF. * Patients previously diagnosed with ROP but not treated for the condition.
Exclusion criteria
* Age below six years at date of examination. * A developmental level not compatible with performing the study examinations. * Patients born or treated outside Norway * Known ocular or systemic disease that can give structural or functional changes in the retina.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Width of the foveal avascular zone | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years | Width of the foveal avascular zone in micrometers measured with optical coherence tomography angiography |
| Choroidal vascularity | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years. | Choroidal vascularity in the macula measured with optical coherence tomography and with choroidal vascularity index in percent |
| Retinal nerve fiber layer thickness | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years. | Retinal nerve fiber layer thickness in micrometers measured with optical coherence tomography |
| Length of persistent avascular retina | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years. | Length of persistent avascular retina measured in millimeters using scanning laser ophthalmoscopy and fluorescein angiography |
| Width of the visual field | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years. | Width of the visual field in degrees measured with Goldmann Perimetry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between cerebral visual impairment and brain hemorrhages | Neonatal period to time for data collection in the current study | Correlation between scores for cerebral visual impairment at time of the study and brain hemorrhages in neonatal period |
| Visual acuity | From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years. | Visual acuity measured with LogMAR. |
Countries
Norway
Contacts
CONTACTErlend Christoffer Sommer Landsend, M.D., Ph.D.
CONTACTAmanda Schjetlein, M.D.
STUDY_CHAIRErlend Christoffer Sommer Landsend, M.D., Ph.D.
Oslo University Hospital
Outcome results
None listed